Handelsavisen
prelaunch
Companies ›Healthcare ›SVRA.O
SV
SVRA.O — NASDAQ Biotechnology

Svra.O

$5,44
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-19 182,9 %
ROE
-77,1 %
Net margin
-19 305,4 %
Debt / equity
0,39
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$5,54
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About

SVRA.O is a biotechnology company within the Health Care sector, though its specific operational activities and revenue generation mechanisms are not detailed in the available data.

Business. SVRA.O is a biotechnology company within the Health Care sector, though its specific operational activities and revenue generation mechanisms are not detailed in the available data.

Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
Wellington Management Company, LLP
largest disclosed fund holder
Profitability→
-77,1 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning SVRA.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to SVRA.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    SVRA.O is a biotechnology company within the Health Care sector, though its specific operational activities and revenue generation mechanisms are not detailed in the available data.

    Classification85 %
    SectorHealth Care
    Industry groupBiotechnology
    AI synthesis
    GENERATED

    (a) Capital structure and liquidity: The company holds total assets of $97.7 million against total liabilities of $33.4 million, resulting in total equity of $64.4 million. Long-term debt stands at $25.1 million, yielding a debt-to-equity ratio of 0.39. Cash and equivalents are reported at $22.9 million. Despite these balances, the risk assessment flags medium liquidity risk and notes that net cash is negative after subtracting total debt, indicating that total debt obligations exceed liquid cash reserves.

    (b) Profitability and returns: The company is not profitable, reporting a net income of -$49.6 million and an operating income of -$49.3 million. This results in a return on equity of -77.06% and a return on assets of -50.76%. These negative returns indicate significant value destruction relative to the capital base in the latest period.

    Key takeaways
    • The company operates in the Biotechnology sector with low classification confidence.
    • Significant losses of -$49.6 million result in negative ROE (-77%) and ROA (-51%).
    • Liquidity is constrained by a negative net cash position despite $22.9 million in cash.
    • Revenue is minimal at $257,000, indicating a pre-commercial stage.
    • Dilution risk is currently assessed as low.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $5,44
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $64.4M
    Net cashⓘ
    -$2.2M
    Current ratioⓘ
    —
    Debt / equityⓘ
    0.4
    ROAⓘ
    -50.8%
    ROEⓘ
    -77.1%
    Cash conversionⓘ
    80.0%
    CapEx / revenueⓘ
    18.3%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution8 analysts
    Strong buy3
    Buy5
    Hold0
    Sell0
    Strong sell0
    12-month price target$10,94 · Median $10,25
    Low $9,00High $16,00
    Operating income · consensus-150,7M USD
    EPS surprise
    +7,5 %
    reported vs consensus · beat
    Revenue surprise
    −100,0 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$9,00
    Mean$10,94
    Median$10,25
    High$16,00
    Spot$5,44
    +101.1 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-19 182,9 %Bottom quartile
    Net Margin-19 305,5 %Bottom quartile
    ROE-77,1 %Bottom quartile
    Capex / Rev18,3 %Best in class
    D/E0,39Bottom quartile
    Cash Conv0,80Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net disposed 1 384 398 sh15 exercises · 2 grants6 insiders
    • Lutz Robert MatthewChief Fin. & Operating Officer · Stock Option (Right to Buy) → Common StockAcquired 70 000 @ $5,81grant · 2026-07-15
    • Lowrance David LChief Financial Officer · Stock Option (Right to Buy) → Common StockDisposed 129 350 @ $1,23exercise · 2026-06-22
    • Lowrance David LChief Financial Officer · Stock Option (Right to Buy) → Common StockDisposed 56 937 @ $1,11exercise · 2026-06-22
    • Lowrance David LChief Financial Officer · Stock Option (Right to Buy) → Common StockDisposed 218 750 @ $1,51exercise · 2026-06-22
    • Lowrance David LChief Financial Officer · Stock Option (Right to Buy) → Common StockDisposed 12 500 @ $4,45exercise · 2026-06-22
    • Lowrance David LChief Financial Officer · Stock Option (Right to Buy) → Common StockDisposed 87 650 @ $3,35exercise · 2026-06-22
    • Lowrance David LChief Financial Officer · Stock Option (Right to Buy) → Common StockDisposed 75 000 @ $1,59exercise · 2026-06-22
    • Lowrance David LChief Financial Officer · Stock Option (Right to Buy) → Common StockDisposed 80 684 @ $1,51exercise · 2026-03-18
    • Lowrance David LChief Financial Officer · Stock Option (Right to Buy) → Common StockDisposed 260 000 @ $1,23exercise · 2026-03-18
    • Lowrance David LChief Financial Officer · Stock Option (Right to Buy) → Common StockDisposed 100 000 @ $1,11exercise · 2026-03-18
    • Lowrance David LChief Financial Officer · Stock Option (Right to Buy) → Common StockDisposed 40 000 @ $4,45exercise · 2026-03-18
    • Lowrance David LChief Financial Officer · Stock Option (Right to Buy) → Common StockDisposed 300 000 @ $3,35exercise · 2026-03-18
    • Lowrance David LChief Financial Officer · Stock Option (Right to Buy) → Common StockDisposed 150 000 @ $1,59exercise · 2026-03-18
    • McCracken Joseph SDirector · Stock Option (right to buy) → Common StockDisposed 1 807 @ $1,76exercise · 2026-02-16
    • Elam Nevan CDirector · Stock Option (Right to Buy) → Common StockDisposed 5 860 @ $1,46exercise · 2025-12-02
    • Hawkins Richard JDirector · Stock Option (Right to Buy) → Common StockDisposed 5 860 @ $1,46exercise · 2025-11-14
    • Wasfi YasmineChief Medical Officer · Stock Option (Right to Buy) → Common StockAcquired 70 000 @ $4,11grant · 2025-10-20

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Capex To Revenue
      capital_expenditure / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    Source documents
    • Savara Inc. Market data — financials · 2026-08-01
    • reconciler_enqueue (reconciler) on SVRA.O · 2026-08-01

    Ownership & reference

    Top holders

    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$15M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$37M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$20M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$6M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$61M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$6M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$32M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$10M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$3M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$3M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$1M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$2M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$1M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$1M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,00 %$0M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$0M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M

    Leadership

    • Matt PaulsChairman of the Board, Chief Executive Officer

    Insider activity

    Net selling0 buys · 2 sellsnet -$2,4M11 insiders · last 365d
    • Lutz Robert MatthewChief Fin. & Operating Officer · Common StockOther 35 000 · 2026-07-15
    • Lowrance David LChief Financial Officer · Common StockOther 60 057 @ $5,50$330K · 2026-06-22
    • Lowrance David LChief Financial Officer · Common StockOther 75 000 @ $1,59$119K · 2026-06-22
    • Lowrance David LChief Financial Officer · Common StockOther 21 682 @ $5,50$119K · 2026-06-22
    • Lowrance David LChief Financial Officer · Common StockOther 129 350 @ $1,23$159K · 2026-06-22
    • Lowrance David LChief Financial Officer · Common StockOther 28 928 @ $5,50$159K · 2026-06-22
    • Lowrance David LChief Financial Officer · Common StockOther 56 937 @ $1,11$63K · 2026-06-22
    • Lowrance David LChief Financial Officer · Common StockOther 11 491 @ $5,50$63K · 2026-06-22
    • Lowrance David LChief Financial Officer · Common StockOther 218 750 @ $1,51$330K · 2026-06-22
    • Lowrance David LChief Financial Officer · Common StockOther 12 500 @ $4,45$56K · 2026-06-22
    • Lowrance David LChief Financial Officer · Common StockOther 10 114 @ $5,50$56K · 2026-06-22
    • Lowrance David LChief Financial Officer · Common StockOther 87 650 @ $3,35$294K · 2026-06-22
    • Lowrance David LChief Financial Officer · Common StockOther 53 387 @ $5,50$294K · 2026-06-22
    • Lowrance David LChief Financial Officer · Common StockSold 394 528 @ $5,68$2,2M · 2026-06-22
    • Lowrance David LChief Financial Officer · Common StockOther 80 684 @ $1,51$122K · 2026-03-18
    • Lowrance David LChief Financial Officer · Common StockOther 24 174 @ $5,04$122K · 2026-03-18
    • Lowrance David LChief Financial Officer · Common StockOther 75 000 @ $1,59$119K · 2026-03-18
    • Lowrance David LChief Financial Officer · Common StockOther 23 661 @ $5,04$119K · 2026-03-18
    • Lowrance David LChief Financial Officer · Common StockOther 130 650 @ $1,23$161K · 2026-03-18
    • Lowrance David LChief Financial Officer · Common StockOther 31 885 @ $5,04$161K · 2026-03-18
    • Lowrance David LChief Financial Officer · Common StockOther 43 063 @ $1,11$48K · 2026-03-18
    • Lowrance David LChief Financial Officer · Common StockOther 9 485 @ $5,04$48K · 2026-03-18
    • Lowrance David LChief Financial Officer · Common StockOther 12 500 @ $4,45$56K · 2026-03-18
    • Lowrance David LChief Financial Officer · Common StockOther 11 037 @ $5,04$56K · 2026-03-18
    • Lowrance David LChief Financial Officer · Common StockOther 24 850 @ $3,35$83K · 2026-03-18

    Short positioning

    34.1Mshares short+6.6% vs prior
    20.82days to cover
    60.0%short of daily vol
    6fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    SVRA.OCanonical
    NASDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    • Operating cash flow (annual): USD -101.04MUnknown
    • Current liabilities (annual): USD 20.4MUnknown
    • Total operating expenses (annual): USD 123.55MUnknown
    • Operating income (annual): USD -123.55MUnknown
    • Capex (annual): USD 22KUnknown
    • Total assets (annual): USD 253.44MUnknown
    • Pre-tax income (annual): USD -118.84MUnknown
    • Shares outstanding (annual): 204.57MUnknown
    • EPS (basic) (annual): USD-PER-SHARES -1Unknown
    • Net income (annual): USD -118.84MUnknown
    • EPS (diluted) (annual): USD-PER-SHARES -1Unknown
    • Total liabilities (annual): USD 50.3MUnknown
    • Shareholders' equity (annual): USD 203.13MUnknown
    • Cash & equivalents (annual): USD 33.18MUnknown
    • Current assets (annual): USD 241.62MUnknown
    • Long-term debt (annual): USD 29.91MUnknown
    • Operating income (annual): USD -103.2MUnknown
    • EPS (basic) (annual): USD-PER-SHARES -0Unknown
    • EPS (diluted) (annual): USD-PER-SHARES -0Unknown
    • Total assets (annual): USD 212.88MUnknown
    • Pre-tax income (annual): USD -95.88MUnknown
    • Shareholders' equity (annual): USD 171.45MUnknown
    • Shares outstanding (annual): 172.42MUnknown
    • Total liabilities (annual): USD 41.43MUnknown
    Showing 24 of 32 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-15INSIDERLutz Robert Matthew transacted 35.0k sh — Chief Fin. & Operating Officer
    2026-07-15INSIDERLutz Robert Matthew acquired 70.0k sh Stock Option (Right to Buy) — Chief Fin. & Operating Officer
    2026-06-22 00:00 UTCINSIDER19 insider transactions — 2026-06 · net sell $2.2M 6 derivative
    2026-06-22 00:00 UTCINSIDER19 insider transactions — 2026-06 · net sell $2.2M 6 derivative
    2026-06-22INSIDERLowrance David L transacted 60.1k sh — Chief Financial Officer ~$330k
    2026-06-22INSIDERLowrance David L transacted 75.0k sh — Chief Financial Officer ~$119k
    2026-06-22INSIDERLowrance David L transacted 21.7k sh — Chief Financial Officer ~$119k
    2026-06-22INSIDERLowrance David L transacted 129.3k sh — Chief Financial Officer ~$159k
    2026-06-22INSIDERLowrance David L transacted 28.9k sh — Chief Financial Officer ~$159k
    2026-06-22INSIDERLowrance David L transacted 56.9k sh — Chief Financial Officer ~$63k
    2026-06-22INSIDERLowrance David L transacted 11.5k sh — Chief Financial Officer ~$63k
    2026-06-22INSIDERLowrance David L transacted 218.8k sh — Chief Financial Officer ~$330k
    2026-06-22INSIDERLowrance David L transacted 12.5k sh — Chief Financial Officer ~$56k
    2026-06-22INSIDERLowrance David L transacted 10.1k sh — Chief Financial Officer ~$56k
    2026-06-22INSIDERLowrance David L transacted 87.7k sh — Chief Financial Officer ~$294k
    2026-06-22INSIDERLowrance David L transacted 53.4k sh — Chief Financial Officer ~$294k
    2026-06-22INSIDERLowrance David L sold 394.5k sh — Chief Financial Officer ~$2.24M
    2026-06-22INSIDERLowrance David L disposed of 75.0k sh Stock Option (Right to Buy) — Chief Financial Officer
    2026-06-22INSIDERLowrance David L disposed of 218.8k sh Stock Option (Right to Buy) — Chief Financial Officer
    2026-06-22INSIDERLowrance David L disposed of 56.9k sh Stock Option (Right to Buy) — Chief Financial Officer
    2026-06-22INSIDERLowrance David L disposed of 129.3k sh Stock Option (Right to Buy) — Chief Financial Officer
    2026-06-22INSIDERLowrance David L disposed of 87.7k sh Stock Option (Right to Buy) — Chief Financial Officer
    2026-06-22INSIDERLowrance David L disposed of 12.5k sh Stock Option (Right to Buy) — Chief Financial Officer
    2026-06-08FILING8-K filing →
    2026-05-12FILING10-Q filing →
    2026-04-24FILINGDEF 14A filing →
    2026-03-18 00:00 UTCINSIDER18 insider transactions — 2026-03 · $1.2M gross 6 derivative
    2026-03-18 00:00 UTCINSIDER18 insider transactions — 2026-03 · $1.2M gross 6 derivative
    2026-03-18INSIDERLowrance David L transacted 80.7k sh — Chief Financial Officer ~$122k
    2026-03-18INSIDERLowrance David L transacted 24.2k sh — Chief Financial Officer ~$122k
    2026-03-18INSIDERLowrance David L transacted 75.0k sh — Chief Financial Officer ~$119k
    2026-03-18INSIDERLowrance David L transacted 23.7k sh — Chief Financial Officer ~$119k
    2026-03-18INSIDERLowrance David L transacted 130.7k sh — Chief Financial Officer ~$161k
    2026-03-18INSIDERLowrance David L transacted 31.9k sh — Chief Financial Officer ~$161k
    2026-03-18INSIDERLowrance David L transacted 43.1k sh — Chief Financial Officer ~$48k
    2026-03-18INSIDERLowrance David L transacted 9.5k sh — Chief Financial Officer ~$48k
    2026-03-18INSIDERLowrance David L transacted 12.5k sh — Chief Financial Officer ~$56k
    2026-03-18INSIDERLowrance David L transacted 11.0k sh — Chief Financial Officer ~$56k
    2026-03-18INSIDERLowrance David L transacted 24.9k sh — Chief Financial Officer ~$83k
    Showing the 40 most recent of 61 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage